The SEC Declared Effective Bodisen Biotech's Recent SB-2 Registration Statement and Bodisen Successfully Hosts Global Fund Managers in Yang Ling
Wednesday June 8, 9:30 am ET

NEW YORK--(BUSINESS WIRE)--June 8, 2005--Bodisen Biotech, Inc., (stock symbol: BBOI, website: /) announced today that its filing of a Post Effective Amendment on Form SB-2 was declared effective by the Securities and Exchange Commission on May 27th, 2005.

Bodisen also announced that the company recently hosted U.S. and European Institutions and Fund managers, for the fourth time in the last twelve months at the company's headquarters in China. The two day event allowed investors to visit Bodisen's new state of the art manufacturing facility, witness the company's daily operations and its strong growth potential. The investors were also introduced to a number of key industry experts and local government officials, who are involved with Bodisen's long term growth plans. For more information and photos of Bodisen's facilities, please visit: /

Ms. Qiong Wang, CEO of Bodisen, commented, "We are pleased to have the SEC review and then declared effective the SB-2 registration statement that we recently filed, which reflects our ongoing commitments as a U.S. public company. Our first quarter 2005 financial report again reflected record earnings. We are on track to achieving another record year in earnings with considerable growth. I was also delighted by the strong interest shown in Bodisen from global fund managers."

About Bodisen Biotech, Inc.

Utilizing proprietary technologies, Bodisen sells over 60 packaged products in 3 product categories throughout China: Organic Compound Fertilizer; Organic Liquid Fertilizer; and Pesticides & Insecticides. Bodisen's organic fertilizers can be absorbed by plants within 48 hours while enriching soil conditions without the damaging effects associated with chemical fertilizers.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Bodisen Biotech, Inc.
Investor Relations, 212-566-3503
info@bodisen.com

Source: Bodisen Biotech, Inc.